The stem cell field is currently engaged in a feisty debate about how to advance innovative research while assuring that clinical translation proceeds safely and prudently. Every new approach comes under scrutiny, but over recent years broad claims about the properties and potential of adult stem cell populations have been a particular focus of concern.
In April, these issues rose to the fore again when scientists at the University of Michigan and New-York-based Neo-Stem Inc. announced plans to launch a first-in-man trial using very small embryonic-like cells (VSELs) to regenerate bone. Many leading stem cell researchers argue that this step is premature. The data on VSELs are much less well established than they are for mesenchymal stem cells, says George Daley, Director of Stem Cell Transplantation at Children's Hospital, Boston, and yet no one to date has proven how to harness MSCs to improve bone healing. Outstanding questions abound, including the very basic one of whether VSELs are in fact cells at all, as opposed to subcellular particles or debris. ''If they have found a new kind of cell with miraculous properties, they certainly haven't established it in a rigorous way that's been convincing to the general community,'' says Daley. Indeed, only a handful of groups have published on VSELs, and an almost equal number of groups have published papers with negative results.
It's a view echoed by Christine Mummery, a professor of developmental biology at Leiden University Medical Center in the Netherlands. ''They are obviously measuring something. But it's difficult to say what,'' she says. ''As long as these cells remain rather odd and the experiments that are published seem slightly less than robust, I think they're open to question.'' Even Mariusz Ratajczak, director of the developmental biology research program at the University of Louisville's James Graham Brown Cancer Center and the lead author of the paper that brought VSELs into the literature, is anxious about the pace at which they are being pushed. ''I'm a little bit scared because I know that NeoStem would like to go fast to the clinic,'' he says. ''I still think we need to do more basic research.'' Back in 2006, Ratajczak and his colleagues, who were working with mice, were the first to describe a population of small cells (around 3.6 mm in diameter) with a thin rim of cytoplasm surrounding a euchromatin-rich nucleus, and apparently boasting a suite of molecular markers characteristic of pluripotent embryonic stem cells. In culture, these cells, which they christened VSEL cells, seemed capable of differentiation into all three germ layer lineages, leading to the suggestion that they ''could be a source of pluripotent stem cells for tissue/organ regeneration.'' (Reviewed in Kassmer et al., 2013) .
Since then, Ratajczak's group and others have described cells with a similar morphological and molecular profile in a broad range of murine tissues, from cord blood and bone marrow to heart and brain, and even in the reproductive organs. Some studies have also suggested that mouse VSELs are highly mobile, with concentrations in the peripheral blood escalating in response to a range of insults, including myocardial infarction, stroke, skin burns, and Crohn's disease (reviewed in Kassmer et al., 2013) .
When the University of Louisville began to circulate the patents it had filed to protect the use of these cells for a range of clinical indications, there was interest from NeoStem, a biopharmaceutical company with a focus on the therapeutic potential of adult cells. ''Our interest was to see if these cells were present in humans,'' says Denis Rodgerson, founder and Director of Stem Cell Science at NeoStem, which acquired the worldwide exclusive license to VSEL technology in 2007. ''It was an intriguing opportunity.'' NeoStem has developed a protocol for the isolation and extraction of what they present as an analogous population of cells in humans and has filed around 20 patent applications protecting the method for isolating these cells and ''a very broad swath of indications that one could imagine using these cells for regenerative purposes,'' says Todd Girolamo, Associate General Counsel at NeoStem.
NeoStem and a range of partner institutions have also obtained an estimated $4.5 million in government grantsnotably from the Department of Defense and NIH-to explore the potential of human VSELs for regenerative medicine. ''We have strong evidence suggesting that these cells will differentiate into all mesenchymal tissue in vivo,'' says Rodgerson. Furthest along the development pipeline, in partnership with researchers at the University of Michigan, Ann Arbor, is research into the differentiation of VSELs into bone. Based on a paper published in February (Havens et al., 2013) , NeoStem is planning to apply for FDA approval to carry out a first-in-man trial using VSELs to regenerate bone following a tooth extraction. ''We certainly want to demonstrate with this first-in-man trial the safety of these V[SEL] cells,'' says Tim Fong, NeoStem's Vice President for Technology and Product Development. ''This will make it easier to think about establishing clinical efficacy and the other indications that NeoStem is interested in.'' But many in the wider stem cell community remain unconvinced. ''To make a robust claim for a new type of 'embryonic-like' cell, you come at it every which way from Sunday,'' says Daley. ''This rigorous approach just hasn't been taken with VSELs. I find the work mystifying and lacking in rigor.'' The relationship that NeoStem has forged with the Vatican through the Stem for Life Foundation (a not-for-profit organization set up by NeoStem to promote the potential of adult stem cells) has also influenced the wider perception of the company and its research. A recent editorial in Nature (Nature, 2013) was scathing about a meeting organized by the Stem for Life Foundation in Vatican City in April: ''Sick children were paraded for television, sharing the stage with stem cell companies and scientists desperate to hawk a message that their therapies must be speeded to clinical use.'' Some in the field have also raised concerns about the potential for the Vatican to exert influence over the scientific focus of Neostem through this connection.
Chris Mason, Chair of Regenerative Medicine Bioprocessing at University College, London attended the conference and begs to differ. ''I was very cautious before I accepted the invitation,'' he says. ''But I did actually see a genuine meeting and genuine dialogue. Unfortunately a lot of the reporting made about that conference was by people who did not attend.'' That said, there are still a lot of unanswered questions about VSELs, says Mason. ''It's all about reproducibility. We need to see more standards, more characterization, and more common assays used that enable us to compare these different cell types and to really know what they do.'' Recent publications have underscored these concerns. For one study, Vita34, a private cord blood bank in Germany, teamed up with researchers at the University of Leipzig to isolate human VSELs from some of their banked samples. In the resulting paper, they claimed to have isolated human VSELs, reporting that they ''failed to expand in vitro under a wide range of culture conditions known to support embryonic or adult stem cell types'' (Danova-Alt et al., 2012) . ''We would have found them if they were there,'' asserts Rü diger Alt, lead author on the paper and now head of research and development at Vita34. ''If they had any sort of proliferative capacity, it should have turned out in our assays, but it didn't.'' Based on this analysis Vita34 is no longer pursuing research into these cells, he says.
For Ratajczak, there is a simple explanation. ''In studying rare populations of cells, one needs to compare apples to apples, which unfortunately was not done,'' he says. ''They did not follow our isolation protocol. All the experiments they performed were performed on the wrong population of cells.'' Ratajczak is similarly dismissive of a study that appeared earlier this year that called into question the reported properties of VSELs, this time in mice (Szade et al., 2013) , and he cites another study claiming to demonstrate the differentiation of VSELs into lung tissue in mice (reviewed in Kassmer et al., 2013) . But an even more recent paper-the most robust effort yet to replicate the isolation of VSELs in mice-may be harder to dismiss. ''We found that every step of the way, we could not confirm the results of the Ratajczak group,'' says Irving Weissman, Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine and the senior author of the article in Stem Cell Reports (Miyanishi et al., 2013) . As a result, Weissman argues that clinical investigation of VSELs is misguided and may be driven more by ideological or commercial hopes for adult (as opposed to embryonic) stem cells than by robust scientific support.
Daley would like to see a rapid resolution to this stalemate. ''The folks who are making negative claims should be encouraged to contact the original lab to refine the isolation protocols,'' he says. But, he adds, ''it should be incumbent upon Ratajczak to share the protocol in a way that's robust and reproducible. It doesn't do the field any good if only one lab has the right hocus pocus to make a technique work.''
Daley cites technical concerns about many aspects of the original VSEL work, which claimed the cells were pluripotent and yet lacked a clear-cut comparison to verified pluripotent stem cells. He would like to see proponents of VSELs use the most rigorous experimental approaches available, such as pluripotent reporter gene expression and lineage tracing in mice, and work with others to ensure reproducibility before moving forward with any type of clinical application. ''Is there a real pluripotent cell here that can be cultured, expanded, and harnessed for therapeutic potential?'' asks Daley. ''Or are they chasing cellular contaminants that can't be easily exploited for clinical application?'' Despite such questions, NeoStem intends to proceed. ''I don't think it's unusual that you have conflicting or controversial data in a field that, in my opinion, is still relatively early in terms of understanding and fully characterizing human V[SEL] cells,'' says Fong. ''The proof will be in the clinical trials that will hopefully come in the future.'' But for others in the wider stem cell field, the pace at which VSELs are being pushed is a cause of considerable concern. ''We need more independent validation of VSELs before clinical introduction,'' says Mummery. ''If these unproven technologies are pushed too hard commercially, there is a real danger that it will raise the expectations of the public. This could be very damaging to the field as a whole.'' Henry Nicholls* London, UK *Correspondence: henry@henrynicholls. com http://dx.doi.org/10.1016/ j.stem.2013.07.003
